Up-to-date List of Adenocard Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Adenocard Medical Research Studies

RankStatusStudy
1 Recruiting Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake
Condition: Coronary Artery Disease
Intervention: Drug: Adenosine
Outcome Measure: Interstitial levels of adenosine
2 Recruiting Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab
Condition: Coronary Artery Disease
Interventions: Drug: adenosine;   Drug: regadenoson;   Drug: Adenosine
Outcome Measures: Difference in FFR and Coronary Flow Reserve measurements between IV adenosine and IV regadenoson;   Monitor for potential side effects after IV adenosine and IV regadenoson administration such as chest pain, headache, flushing, nausea or arrhythmias
3 Recruiting Determining the Optimal Adenosine Provocation Test
Condition: Asthma
Intervention: Other: Bronchial provocation test
Outcome Measures: The small airway reaction to provocation with adenosine, reflected by the IOS parameter R5-R20;   The total airway reaction to provocation with adenosine, reflected by the decline in FEV1 (PD20/ PC20 values)
4 Recruiting Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation
Condition: Atrial Fibrillation
Intervention: Drug: Adenosine arm
Outcome Measures: Pulmonary vein reconnection;   AF recurrence;   Adverse effects atrial fibrillation ablation
5 Recruiting Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler
Condition: Ischemic Heart Disease
Intervention: Drug: adenosine + dipyridamole
Outcome Measures: Diastolic mean and peak coronary blood velocities;   Incidence rate and severity of adverse events, in particular, chest pain, dyspnoea, hypotension, bradycardia, AV blocks, arrhythmia.
6 Recruiting Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
Condition: Coronary Artery Disease
Intervention: Drug: FFR Measurement with IV Adenoscan® then with Regadenoson
Outcome Measure: Comparing measurement of Fractional Flow Reserve (FFR)
7 Unknown  Stress Adenosine Cardiac Magnetic Resonance (MR) Comparison With Single Photon Emission Computed Tomography (SPECT) Imaging
Conditions: Coronary Artery Disease;   Cardiac Perfusion
Interventions: Procedure: SPECT Imaging;   Procedure: Stress Adenosine CMR
Outcome Measure: Stress adenosine cardiac MRIis not inferior to SPECT imaging in diagnosing myocardial ischemia
8 Recruiting Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)
Conditions: Atrial Fibrillation;   Persistent Common Pulmonary Vein
Intervention: Drug: Adenosine arm
Outcome Measures: Reconnection of pulmonary vein electrogram after adenosine infusion;   Atrial fibrillation recurrence
9 Recruiting PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation
Condition: Paroxysmal Atrial Fibrillation
Intervention: Procedure: PVAI followed by adenosine provocation
Outcome Measure: AF recurrence
10 Unknown  Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement
Conditions: Coronary Artery Disease;   Myocardial Ischemia
Interventions: Other: Maximal Hyperemia with Adenosine Followed by Nicorandil;   Other: Maximal Hyperemia with Nicorandil Followed by Adenosine
Outcome Measures: Fractional Flow Reserve at Maximal Hyperemia;   Time to Maximal Hyperemia;   Changes in Heart Rate
11 Unknown  Salvage: Postconditioning With Adenosine for STEMI
Condition: Acute ST Elevation Myocardial Infarction
Intervention: Drug: Adenosine
Outcome Measures: Beneficial Effect of Intracoronary Adenosine on Microvascular and Myocardial Salvage in Patients With Acute Myocardial Infarction;   By means of:;   1. MR imaging;   - at day 2-3: Rest perfusion, MVO, late enhancement and function;   - at 4 months: Rest perfusion, late enhancement and function;   2. Tissue Doppler Imaging;   At 16-36 hours: Resolution of edema/wall thickness increase Function;   At 4 months;   3 Quantitative Coronary Angiography;   TIMI flow grade, TIMI frame count on angiography of the IRA and myocardial blush grade before and at completion of the primary PCI procedure will be performed.;   4 Electrocardiographic Analysis;   - ST segment resolution will be assessed from the 12–lead ECG on admission and the ECG on admission on C.C.U. after the PCI–procedure. This will be examined for summed ST deviation and for ST deviation in the single lead with maximal ST–deviation on;   Finally, the last ECG before hospital discharge and an ECG at 4 months will be studied for the evolution of Q-waves and T-waves.;   - 24 hour continuous ST-segment recording in the single lead with maximal ST-deviation on admission with calculation of the area under the curve.;   5 Echocardiographic evaluation of left ventricular function;   At 16-36 hours;   After 4 months;   6 Cardiac markers;   Blood samples for determination of the MB fraction of creatinekinase and of troponin I are to be taken:;   On admission;   Before and after PCI, through the sheath;   At 90 minutes after PCI;   At 8 hours after PCI;   At 16 hours after PCI;   At 24 hours after PCI;   7 Clinical follow-up;   Occurrence of MACE (death, new Q-wave or non Q-wave MI or target vessel revascularisation) and the presence of clinical signs of heart failure will be recorded;   At hospital discharge;   At 30 days;   At 6 months
12 Unknown  Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia
Condition: Supraventricular Tachycardia
Interventions: Drug: Dexmedetomidine;   Drug: Adenosine
Outcome Measures: Termination of SVT;   Incidence and duration of sinus pause or asystole after termination of SVT;   Incidence of Tachyarrhythmias;   Hypotension and hypertension
13 Recruiting Study Evaluating the Use of Vasodilators to Reduce Infarct Size and Microvascular Obstruction in ST-elevation MI
Condition: ST-elevation Myocardial Infarction (STEMI)
Interventions: Drug: IC Adenosine;   Drug: IC Sodium nitroprusside (SNP);   Procedure: Standard PCI
Outcome Measures: CMR measured infarct size (% LV mass);   CMR incidence and extent of MVO (% LV mass);   CMR measured myocardial salvage index, haemorrhage, LV EF and volumes;   Myocardial Blush Grade assessed by validated computer software 'Quantitative Blush Evaluator' (QuBE;   Incidence pre- and post- procedure angiographic true "no-reflow";   Any in-patient clinical events;   Overall MACE;   Degree of ST segment resolution on ECG;   Echocardiographic assessment of LV;   Corrected TIMI Frame Count
14 Unknown  Adenosine Testing to DEtermine the Need for Pacing Therapy
Condition: Syncope
Interventions: Device: Pacemaker implantation (Medtronic);   Device: Implantable Loop Recorder (Medtronic)
Outcome Measures: Syncope Burden;   Time to first syncope;   Number of patients with recurrent syncope;   Quality of life;   Health economic analysis;   ECG diagnosis on ILR following syncopal episode in adenosine negative group
15 Recruiting Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
Outcome Measures: Immunological reconstitution;   Incidence of adverse reactions;   Molecular characterisation of gene transfer;   Normalisation of nutritional status, growth, and development
16 Recruiting Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions
Conditions: Arthrogryposis;   Craniofacial Abnormalities
Interventions: Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels;   Procedure: Physiological Stress Test;   Other: Functional Enquiry Form;   Other: Strength, Joint ROM, Girth and Length Measurements;   Other: Study Physical Examination;   Other: Observational Gait Analysis;   Other: Mental Health Interview
Outcome Measures: Heart rate;   Non-Invasive Arterial Blood Pressure;   Lung Volumes;   Saturation of Peripheral Oxygen;   Respiratory Rate;   Electrocardiogram Tracings;   Oesophageal (Core) Temperature;   Adenosine Triphosphate Blood Levels;   Borg Scale Ratings of Perceived Exertion;   Muscle Rigidity;   Medical Outcomes Trust Short Form (36) Health Survey (SF-36)
17 Unknown  Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Conditions: Heart Disease, Ischemic;   Atherosclerosis, Coronary
Intervention: Drug: adenosine
Outcome Measures: Compare sensitivity and specificity in detection of significant coronary artery disease in patients that had been referred to the Catheterization Lab with suspected ischemic disease using the comprehensive cardiac Magnetic Resonance Imaging protocol;   Number of participants with adverse events to demonstrate feasibility of a comprehensive cardiac Magnetic Resonance Imaging protocol
18 Not yet recruiting Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
Conditions: Peripheral Artery Disease;   Vascular Disease;   Arterial Occlusion Disease;   Intermittent Claudication;   Ankle Brachial Index (0.9 or Less)
Interventions: Drug: Ticagrelor;   Drug: clopidogrel
Outcome Measures: Assessment of ticagrelor when compared to clopidogrel on adenosine-induced myocardial blood flow (MBF) by cardiac 13N ammonia Positron EmissionTomography (PET) at Visit 2;   Assessment of ticagrelor when compared to clopidogrel on adenosine-induced myocardial blood flow (MBF) by cardiac 13N ammonia Positron EmissionTomography (PET) at Vist 3
19 Recruiting Study on Reflex Response During Temporary Stimulation and Inhibition of Chemoreceptors of Carotid Bodies - a Pilot Study
Conditions: Heart Failure;   Peripheral Chemoreceptor Hypersensitivity
Intervention: Drug: Adenosine
Outcome Measures: Ventilation at rest;   Arterial blood pressure;   ECG;   Capillary blood saturation;   Breathing pattern
20 Recruiting Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions
Conditions: Arthrogryposis;   Craniofacial Abnormalities;   Posttraumatic Stress Disorder;   Depressive Disorder
Interventions: Other: PTSD Checklist-Specific;   Other: Modified Flanagan Quality of Life Scale;   Other: Center for Epidemiologic Studies Depression Scale;   Other: Functional Enquiry Form;   Other: Strength, Joint ROM, Girth and Length Measurements;   Other: Study Physical Examination;   Other: PTSD, Depression, and FSS-Focused Examination;   Other: Freeman-Sheldon Specific Quality of Life Survey;   Other: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Outcome Measures: Situational Mental Health in Persons with FSS or Related Condition;   Situational Mental Health in Family and Others Close to a Person with FSS or Related Condition;   Current Survey Correlation with Disorder-Specific Survey for FSS and Related Conditions

These studies may lead to new treatments and are adding insight into Adenocard etiology and treatment.

A major focus of Adenocard research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Adenocard

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us